Lenacapavir, sold as Sunlenca by Gilead, currently costs $42,250 for the first year, but could be available at $40 a year, making it a breakthrough for affordable HIV prevention.
Experts calculated the minimum price for mass production of lenacapavir's generic version, allowing for 30% profit, to be $40 a year if 10 million people used it annually, potentially benefiting 60 million people in the long-term.
Dr. Andrew Hill highlighted lenacapavir's potential, stating it offers close to 100% protection with an injection every six months, akin to an HIV vaccine breakthrough compared to current daily prevention methods.
[
Collection
]
[
|
...
]